On December 10 JSC Olainfarm organized its third quarter 2012 Investor Conference Online Webinar for investors. During the webinar the member of the management board of Olainfarm Salvis Lapiņš analysed the financial results of third quarter 2012 and informed about the company’s future activities.
As Salvis Lapiņš informed during the webinar Olainfarm budget forecast for 2012 is 48 M LVL with net profit 8,6 M LVL. Based on 9 months results, current turnover has reached 73.3% of target and net profit – 74.2%, therefore company is positive about reaching, and even exceeding its budget forecast by the end of the year.
Answering the questions sent in by the investors, Salvis Lapiņš informed that Olainfarm is also actively working to expand on Turkish and Polish markets. Also the daughter company – Olaines enerģija has recently (from the beginning of December, 2012) started to produce energy for JSC Olainfarm production facilities and Olainfarm is no longer purchasing gas from Latvijas gāze. However it is too early to judge on potential financial gains.
The recorded Olainfarm webinar is available online: http://ej.uz/OLFdecember_REC, and the presentation, demonstrated during the webinar, can be found in the previously published Olainfarm announcement: https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=533560&messageId=656679.
Olainfarm thanks all participants, who joined the webinar, and encourages everybody to follow company’s announcements to get information on the next webinar!
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Information prepared by:
Member of the Board
Tel: +371 6 7013 717
Cell: +371 2 6448 873